have to agree with you Risk - I suspect the decisi
Post# of 30027
Which ever direction they proceed with now, it will act like a dye being cast, and may well affect any other larger revenue considerations down the road which might be too late at that time, due to revenue paths choosen earlier - kind of like the why accept x now when you can have xxx later.
They'll figure it out. However like a number here have already expressed, I would rather see an outright sale of LymPro and/or Dx division now then a spinn off where we recieve a dividend or addit. shares.
I suspect a hefty buy out of the Dx Div. would enable them to proceed with MANF and Phenoguard unencumbered buy much additional debt or more dilution to what has already beed experienced.